Visceral Pleural Invasion May Impact Survival in Node-Negative NSCLC

Share this content:
Visceral pleural invasion may have an impact on survival in node-negative non-small cell lung cancer.
Visceral pleural invasion may have an impact on survival in node-negative non-small cell lung cancer.

Visceral pleural invasion (VPI), an aggressive and invasive factor, may have an impact on survival in node-negative non-small cell lung cancer (NSCLC), according to an article published in Chest.1

Investigators conducted a meta-analysis with 13 relevant studies that included 27,171 patients with node-negative NSCLC, and 21% had VPI. VPI had a significant impact on 5-year overall survival (OS) in patients with tumor size ≤3 cm (odds ratio [OR], 0.71: 95% CI, .64-.79; P<.001), >3 but ≤5 cm (OR, .69; 95% CI, .56-.86; P<.001), and >5 but ≤7 cm (OR, .70; 95% CI, .54-.91; P=.007).

When compared to stage 1B NSCLC, tumor size ≤3 cm plus VPI displayed improved survival over tumor size >3 but ≤5 cm independent of VPI presence (OR, 1.31; 95% CI, 1.19-1.45; P<.001).

RELATED: FDA Approves Pembrolizumab for Metastatic Non-Small Cell Lung Cancer

In an exploratory analysis, tumor size ≤3 cm plus VPI did not possess a significant OS benefit over tumor size >3 but ≤5 cm without VPI (OR, 1.16; 95% CI, .95-1.43; P=.15) but was associated with a better prognosis.

Authors concluded that because VPI and tumor size can synergistically impact survival in node-negative NSCLC, adjuvant chemotherapy after surgical resection may be considered in patients with stage 1B NSCLC. Additional clinical trials are required to investigate this further.

Reference

  1. Long J, Liang W, Shen J, et al. The impact of visceral pleural invasion in node-negative non-small cell lung cancer: a systematic review and meta-analysis. Chest. 2015;148(4):903-911.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters